Powered by innovation
2022 lugpa annual meeting
November 10-12
Booth 409
Chicago Marriott Downtown Magnificent Mile Hotel
PROSTATENOW™ is a comprehensive germline test for people who have been diagnosed with prostate cancer or have a family history of prostate cancer or other hereditary cancer disorders. This test can aid in predicting risk levels associated with cancer progression or disease development, as well as in identifying potential targeted therapy options. PROSTATENOW™ was developed in collaboration with NorthShore University HealthSystem and is the only commercially available germline panel that incorporates three screening methods (family history, rare pathogenic mutations (RPMs), and genetic risk score (GRS)) for a comprehensive inherited prostate cancer risk assessment.
Family History (FH)Family History (FH) is a common but indirect measurement of inherited risk. Those with a family history of prostate cancer have a 1.5-to-2.5-fold increased risk of developing prostate cancer.
Rare Pathogenic Mutations (RPMs)Rare Pathogenic Mutations (RPMs) are pathogenic DNA mutations in the coding regions of genes known to be associated with prostate cancer, such as ATM, BRCA2, and CHEK2. RPMs are associated with both an increased risk for developing prostate cancer and more aggressive tumor behavior.
Genetic Risk Score (GRS)Genetic Risk Score (GRS) is calculated based on analysis of >200 single nucleotide polymorphisms (SNPs) known to be associated with prostate cancer. GRS is used to assess a man’s risk of developing prostate cancer compared to other men in the general population.
PROSTATENOW™ provides clinically actionable information for patients who have been diagnosed with or have an increased risk for prostate cancer. In patients with localized disease, PROSTATENOW™ supplements traditional clinical variables like Gleason score and PSA levels in determining risk for disease progression, and can aid in treatment planning. For those with advanced disease, PROSTATENOW™ can offer insights into treatment response and potential targeted therapies, such as PARP-inhibitors. For unaffected men with a family history of prostate cancer, this comprehensive inherited risk assessment can inform decisions regarding prostate cancer screening.
This COMPREHENSIVE GERMLINE PANEL analyzes 88 clinically-relevant genes that are associated with genetic disorders, including most hereditary cancers. Appropriate interpretation of results together with a genetic counselor can help clinicians to provide guidance to patients regarding clinical risk and genetic causes of diseases. The assay detects single- and multi-nucleotide substitutions and small insertions and deletions in coding regions and exon-intron junctions, as well as large genomic rearrangements of the target genes. The assay provides >1500X average coverage at the targeted genomic regions of the tested genes.
LYNCHNOW® is a comprehensive germline screening tool to test for Lynch syndrome and other hereditary cancer disorders in patients with colorectal cancer. This test is designed for colorectal cancer patients with a positive family history of hereditary cancers or a suspicion of Lynch syndrome (e.g. MSI-high or mismatch repair deficiency (dMMR)). We offer two iterations of the test: LYNCHNOW® Basic, which screens the Lynch Syndrome genes (MLH1, MSH2, MHS6, PMS2, EPCAM), and LYNCHNOW® Extended, a comprehensive 31-gene panel that identifies alterations in genes associated with Lynch syndrome and other hereditary disorders related to increased risk for colorectal cancer. Reflex options are available. Both versions of the assay utilize next-generation sequencing and detect single- and multi-nucleotide substitutions and small insertions and deletions in coding regions and exon-intron junctions, as well as large genomic rearrangements of the target genes, providing >1500X average coverage at the targeted genomic regions of the tested genes.
BRCANOW® is a next-generation sequencing panel for people with a personal or family history of breast or ovarian cancer. For comprehensive hereditary screening, we offer two versions of the BRCANow test, BRCANOW® Basic and BRCANOW® Extended, with reflex options available. In addition to BRCA1 & BRCA2, which account for the majority of hereditary breast and ovarian cancers, the BRCANOW® Extended panel includes additional genes that are less common, but known to be associated with hereditary breast and ovarian cancers. Both versions of the assay utilize next-generation sequencing to detect single- and multi-nucleotide substitutions and small insertions and deletions in coding regions and exon-intron junctions, as well as large genomic rearrangements of the target genes, providing >1500X average coverage at the targeted genomic regions of the tested genes.
Begin the Journey
Visit us at Booth 409
